Dazhuan Eric Xin, Yunfei Liao, Rohit Rao, Sean Ogurek, Soma Sengupta, Mei Xin, William L Seibel, Richard T Graham, Carl Koschmann, Q Richard Lu
BACKGROUND: Diffuse intrinsic pontine gliomas (DIPG/DMG) are devastating pediatric brain tumors with extraordinarily limited treatment options and uniformly fatal prognosis. Histone H3K27M mutation is a common recurrent alteration in DIPG and disrupts epigenetic regulation. We hypothesize that genome-wide H3K27M-induced epigenetic dysregulation makes tumors vulnerable to epigenetic targeting. METHODS: We performed a screen of compounds targeting epigenetic enzymes to identify potential inhibitors for the growth of patient-derived DIPG cells...
November 27, 2023: Neuro-oncology
Ethan Chen, Alexander L Ling, David A Reardon, E Antonio Chiocca
Glioblastoma (GBM)'s median overall survival is almost 21 months. Six phase 3 immunotherapy clinical trials have recently been published, yet 5/6 did not meet approval by regulatory bodies. For the sixth, approval is uncertain. Trial failures result from multiple factors, ranging from intrinsic tumor biology to clinical trial design. Understanding the clinical and basic science of these 6 trials is compelled by other immunotherapies reaching the point of advanced phase 3 clinical trial testing. We need to understand more of the science in human GBMs in early trials: the "window of opportunity" design may not be best to understand complex changes brought about by immunotherapeutic perturbations of the GBM microenvironment...
November 23, 2023: Neuro-oncology
Alexander J Schupper, Shrey Patel, Jeremy M Steinberger, Isabelle M Germano
BACKGROUND: Metastatic spine disease (MSD) occurs commonly in cancer patients causing pain, spinal instability, devastating neurological compromise and decreased quality of life. Oncological patients are often medically complex and frail, precluding them form invasive procedures. To address this issue, minimally invasive spinal surgery (MISS) techniques are desirable. The aim of this study is to review published peer-reviewed literature and ongoing clinical trials to provide current state of the art...
November 21, 2023: Neuro-oncology
David R Raleigh, Matthias Preusser
No abstract text is available yet for this article.
November 15, 2023: Neuro-oncology
Matthew K Summers, Monica Venere
No abstract text is available yet for this article.
November 14, 2023: Neuro-oncology
Jason Fangusaro, David T Jones, Roger J Packer, David H Gutmann, Till Milde, Olaf Witt, Sabine Mueller, Michael J Fisher, Jordan R Hansford, Uri Tabori, Darren Hargrave, Pratiti Bandopadhayay
The most common childhood central nervous system (CNS) tumor is pediatric low-grade glioma (pLGG), representing 30%-40% of all CNS tumors in children. Although there is high associated morbidity, tumor-related mortality is relatively rare. pLGG is now conceptualized as a chronic disease, underscoring the importance of functional outcomes and quality-of-life measures. A wealth of data has emerged about these tumors, including a better understanding of their natural history and their molecular drivers, paving the way for the use of targeted inhibitors...
November 7, 2023: Neuro-oncology
Şevin Turcan
No abstract text is available yet for this article.
November 6, 2023: Neuro-oncology
Alexander L Ling, E Antonio Chiocca
No abstract text is available yet for this article.
November 6, 2023: Neuro-oncology
Jiaying Zheng, Lingxiao Wang, Shunyi Zhao, Wenjing Zhang, Yuzhou Chang, Dale B Bosco, Tao Huang, Aastha Dheer, Shan Gao, Shengze Xu, Katayoun Ayasoufi, Rawan Al-Kharboosh, Fangfang Qi, Manling Xie, Aaron J Johnson, Haidong Dong, Alfredo Quiñones-Hinojosa, Long-Jun Wu
BACKGROUND: Myeloid cells comprise up to 50% of the total tumor mass in glioblastoma (GBM) and have been implicated in promoting tumor progression and immunosuppression. Modulating the response of myeloid cells to the tumor has emerged as a promising new approach for cancer treatment. In this regard, we focus on the Triggering Receptor Expressed on Myeloid cells 2 (TREM2), which has recently emerged as a novel immune modulator in peripheral tumors. METHODS: We studied the TREM2 expression profile in various patient tumor samples and conducted single-cell transcriptomic analysis in both glioblastoma patients and the GL261 mouse glioma model...
November 6, 2023: Neuro-oncology
S Derby, L Dutton, K E Strathdee, K Stevenson, A Koessinger, M Jackson, Yuling Tian, Wenxi Yu, K Mclay, J Misquitta, S Alsharif, C J Clarke, L Gilmour, P Thomason, E McGhee, C L McGarrity-Cottrell, A Vanderlinden, S J Collis, O Rominyi, L Lemgruber, G Solecki, M Olson, F Winkler, L M Carlin, D H Heiland, G Inman, A J Chalmers, J C Norman, R Carruthers, J L Birch
BACKGROUND: Glioblastomas have highly infiltrative growth patterns that contribute to recurrence and poor survival. Despite infiltration being a critical therapeutic target, no clinically useful therapies exist which counter glioblastoma invasion. Here, we report that inhibition of Ataxia telangiectasia and Rad 3 related kinase (ATR) reduces invasion of glioblastoma cells through dysregulation of cytoskeletal networks and subsequent integrin trafficking. METHODS: Glioblastoma motility and invasion were assessed in vitro and in vivo in response to ATR inhibition (ATRi) and ATR over-expression using timelapse microscopy, two orthotopic glioblastoma models and intravital imaging...
November 4, 2023: Neuro-oncology
John DeSisto, Andrew M Donson, Andrea M Griesinger, Rui Fu, Kent Riemondy, Jean Mulcahy Levy, Julie A Siegenthaler, Nicholas K Foreman, Rajeev Vibhakar, Adam L Green
BACKGROUND: Pediatric high-grade gliomas (PHGG) are aggressive brain tumors with five-year survival rates ranging from less than 2% to 20% depending upon subtype. PHGG presents differently from patient to patient and is intratumorally heterogeneous, posing challenges in designing therapies. We hypothesized that heterogeneity occurs because PHGG comprises multiple distinct tumor and immune cell types in varying proportions, each of which may influence tumor characteristics. METHODS: We obtained 19 PHGG samples from our institution's pediatric brain tumor bank...
November 2, 2023: Neuro-oncology
(no author information available yet)
No abstract text is available yet for this article.
November 1, 2023: Neuro-oncology
Kelly M Hotchkiss, Eugene Cho, Mustafa Khasraw
No abstract text is available yet for this article.
October 31, 2023: Neuro-oncology
F F Siebenga, H L van der Weide, F Gelmers, S E Rakers, M C A Kramer, A van der Hoorn, R H Enting, I Bosma, R J M Groen, H R Jeltema, M Wagemakers, J M Spikman, A M Buunk
BACKGROUND: Patients with low-grade gliomas (LGG) treated with surgery, generally function well and have a favourable prognosis. However, LGG can affect neurocognitive functioning. To date, little is known about social cognition (SC) in these patients, although impaired SC is related to social-behavioral problems and poor societal participation. Frontal brain areas are important for SC and LGG frequently have a frontal location. Therefore, the aim of the present study was to investigate whether emotion recognition, a key component of SC, was impaired, and related to general cognition, tumor location laterality, tumor volume and histopathological characteristics in patients with LGG, post-surgery and before start of adjuvant therapy...
October 31, 2023: Neuro-oncology
Miguel Cosenza-Contreras, Agnes Schäfer, Justin Sing, Lena Cook, Maren N Stillger, Chia-Yi Chen, Jose Villacorta Hidalgo, Niko Pinter, Larissa Meyer, Tilman Werner, Darleen Bug, Zeno Haberl, Oliver Kübeck, Kai Zhao, Susanne Stei, Anca Violeta Gafencu, Radu Ionita, Felix M Brehar, Jaime Ferrer-Lozano, Gloria Ribas, Leo Cerdá-Alberich, Luis Martí-Bonmatí, Christopher Nimsky, Alexis Van Straaten, Martin L Biniossek, Melanie Föll, Nina Cabezas-Wallscheid, Jörg Büscher, Hannes Röst, Armelle Arnoux, Jörg W Bartsch, Oliver Schilling
BACKGROUND: There is an urgent need to better understand the mechanisms associated with the development, progression, and onset of recurrence after initial surgery in glioblastoma (GBM). The use of integrative phenotype-focused -omics technologies such as proteomics and lipidomics provides an unbiased approach to explore the molecular evolution of the tumor and its associated environment. METHODS: We assembled a cohort of patient-matched initial (iGBM) and recurrent (rGBM) specimens of resected GBM...
October 26, 2023: Neuro-oncology
Kamran Abbasi, Parveen Ali, Virginia Barbour, Thomas Benfield, Kirsten Bibbins-Domingo, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Robert Mash, Peush Sahni, Wadeia Mohammad Sharief, Paul Yonga, Chris Zielinski
No abstract text is available yet for this article.
October 25, 2023: Neuro-oncology
Rotem Gershon, Antonina Polevikov, Yevgeny Karepov, Anatoly Shenkar, Idan Ben-Horin, Tal Alter Regev, Meytal Dror-Levinsky, Kelly Lipczyc, Lital Gasri-Plotnitsky, Gil Diamant, Nati Shapira, Barak Bensimhon, Aharon Hagai, Tal Shahar, Rachel Grossman, Zvi Ram, Ilan Volovitz
BACKGROUND: GBM is an aggressive grade 4 primary brain tumor (BT), with a 5%-13% 5-year survival. Most human GBMs manifest as immunologically "cold" tumors, or "immune deserts", yet the promoting or suppressive roles of specific lymphocytes within the GBM tumor microenvironment (TME) is of considerable debate. PATIENTS AND METHODS: We used meticulous multiparametric flow cytometry (FC) to determine the lymphocytic frequencies in 102 GBMs, lower-grade gliomas, brain metastases, and non-tumorous brain specimen...
October 23, 2023: Neuro-oncology
Shannon Coy, Jong Suk Lee, Sabrina J Chan, Terri Woo, Jacquelyn Jones, Sanda Alexandrescu, Patrick Y Wen, Peter K Sorger, Keith L Ligon, Sandro Santagata
BACKGROUND: Antibody-drug conjugates (ADCs) enhance the specificity of cytotoxic drugs by directing them to cells expressing target antigens. Multiple ADCs are FDA-approved for solid and hematologic malignancies, including those expressing HER2, TROP2, and NECTIN4. Recently, an ADC targeting HER2 (Trastuzumab-Deruxtecan) increased survival and reduced growth of brain metastases in treatment-refractory metastatic breast cancer, even in tumors with low HER2 expression. Thus, low-level expression of ADC targets may be sufficient for treatment responsiveness...
October 23, 2023: Neuro-oncology
Zirong Huo, Zhaohui Wang, Huahong Luo, Dilihumaer Maimaitiming, Tao Yang, Huihui Liu, Huipeng Li, Hao Wu, Zhihua Zhang
BACKGROUND: Vestibular schwannoma (VS) is the most common benign tumor in the cerebellopontine angle and internal auditory canal. Illustrating the heterogeneous cellular components of VS could provide insights into its various growth patterns. METHODS: Single-cell RNA sequencing was used to profile transcriptomes from 7 VS samples and 2 normal nerves. Multiplex immunofluorescence was employed to verify the dataset results. Bulk RNA sequencing was conducted on 5 normal nerves and 44 VS samples to generate a prediction model for VS growth...
October 20, 2023: Neuro-oncology
Jung Oh Lee, Sung Soo Ahn, Kyu Sung Choi, Junhyeok Lee, Joon Jang, Jung Hyun Park, Inpyeong Hwang, Chul-Kee Park, Sung Hye Park, Jin Wook Chung, Seung Hong Choi
BACKGROUND: To investigate the prognostic value of spatial features from whole-brain MRI using a three-dimensional (3D) convolutional neural network (CNN) for adult-type diffuse gliomas. METHODS: In a retrospective, multicenter study, 1,925 diffuse glioma patients were enrolled from five datasets: SNUH (n=708), UPenn (n=425), UCSF (n=500), TCGA (n=160), and Severance (n=132). The SNUH and Severance datasets served as external test sets. Pre- and postcontrast 3D T1-weighted, T2-weighted, and T2-FLAIR images were processed as multichannel 3D images...
October 19, 2023: Neuro-oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.